Sculptor Capital LP Takes Position in Thermo Fisher Scientific Inc. $TMO

by · The Markets Daily

Sculptor Capital LP purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) during the second quarter, Holdings Channel reports. The institutional investor purchased 41,000 shares of the medical research company’s stock, valued at approximately $20,556,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. High Note Wealth LLC boosted its holdings in shares of Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after purchasing an additional 29 shares during the period. Swiss RE Ltd. purchased a new stake in Thermo Fisher Scientific in the 4th quarter worth approximately $28,000. Kilter Group LLC purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at $25,000. Birchwood Financial Partners Inc. purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $29,000. Finally, Legacy Wealth Managment LLC ID grew its stake in Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 22 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $627.96 on Wednesday. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The firm has a fifty day simple moving average of $548.75 and a 200-day simple moving average of $510.05. The stock has a market capitalization of $232.19 billion, a price-to-earnings ratio of 33.78, a PEG ratio of 2.56 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $647.00.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. Thermo Fisher Scientific’s revenue was up 10.5% compared to the same quarter last year. During the same period last year, the business posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is currently 10.11%.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on TMO shares. Evercore set a $570.00 price target on Thermo Fisher Scientific in a research note on Monday, July 6th. Piper Sandler boosted their price target on Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a “neutral” rating in a research note on Monday, July 27th. Jefferies Financial Group reaffirmed a “buy” rating and set a $630.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Wolfe Research started coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price target on the stock. Finally, Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $619.41.

Read Our Latest Report on TMO

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $629.27, for a total transaction of $6,292,700.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at $77,982,284.75. The trade was a 7.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael D. Shafer sold 25,500 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the sale, the executive vice president owned 20,994 shares in the company, valued at approximately $12,596,400. The trade was a 54.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 73,493 shares of company stock worth $43,950,381 over the last 90 days. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Featured Stories

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).